FACscan Analysis of Immunofluorescence Assays Performed on PBMC and Cell Subsets Purified From HCV-Infected Patients
| Antibodies* . | CD Tested . | Cell-151 . | Percent Detection . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Before Selection . | After Selection Using Antibodies Directed Against*: . | ||||||||
| Total Events . | CD45+ -152 . | CD3 . | CD15 . | CD19 . | CD14 . | Neg Fraction-153 . | |||
| M833 | CD45RB | PBMC | 62.3 | 100 | 100 | 100 | 95-155 | 100 | 38¶ |
| Leu4 | CD3 | T lymphocytes | 35.3 | 59.3 | 99 | 3 | <1 | <1 | 37 |
| Leu12 | CD19 | B lymphocytes | 6.9 | 11.6 | <1 | <1 | 94 | <1 | <1 |
| LeuM1 | CD15 | Granulocytes | 20.5 | 24.9 | <1 | 96 | <1 | <1 | <1 |
| LeuM3 | CD14 | Monocytes | 8.2 | 13.8 | <1 | <1 | <1 | 79 | <1 |
| CD42a | Platelets | 9.5 | x | <1 | <1 | <1 | <1 | 52 | |
| Antibodies* . | CD Tested . | Cell-151 . | Percent Detection . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Before Selection . | After Selection Using Antibodies Directed Against*: . | ||||||||
| Total Events . | CD45+ -152 . | CD3 . | CD15 . | CD19 . | CD14 . | Neg Fraction-153 . | |||
| M833 | CD45RB | PBMC | 62.3 | 100 | 100 | 100 | 95-155 | 100 | 38¶ |
| Leu4 | CD3 | T lymphocytes | 35.3 | 59.3 | 99 | 3 | <1 | <1 | 37 |
| Leu12 | CD19 | B lymphocytes | 6.9 | 11.6 | <1 | <1 | 94 | <1 | <1 |
| LeuM1 | CD15 | Granulocytes | 20.5 | 24.9 | <1 | 96 | <1 | <1 | <1 |
| LeuM3 | CD14 | Monocytes | 8.2 | 13.8 | <1 | <1 | <1 | 79 | <1 |
| CD42a | Platelets | 9.5 | x | <1 | <1 | <1 | <1 | 52 | |
*Immunomagnetic selection and antibodies as described in Materials and Methods, 10,000 events were counted and analyzed for each antibody.
Subset of cells expressing the corresponding CD.
Percentage of fluorescent cells when CD45+ cells = 100%.
Negative fraction collected at the end of the last immunomagnetic selection.
The CD45− cells were dead cells (<5%) and erythrocytes (23% of the events).
¶The CD45− cells were dead cells.